Results 1 to 10 of about 1,111,739 (268)

Cryptogenic Fibrosing Pleuritis

European Journal of Case Reports in Internal Medicine, 2021
We report the case of a 46-year-old male patient who was referred for chest pain and bilateral pleural effusion. Despite treatment with antibiotics and steroids, the pleural effusion worsened over a few months until pulmonary function was halved.
Alessandra Anna Manco, Veronica Alfieri, Letizia Gnetti, Marina Aiello, Giuseppina Bertorelli, Maria Majori, Alfredo Chetta   +6 more
doaj   +1 more source

The COPD assessment test and the modified Medical Research Council scale are not equivalent when related to the maximal exercise capacity in COPD patients

Pulmonology, 2023
Introduction The management and treatment of Chronic Obstructive Pulmonary Disease (COPD) are based on a cutoff point either of ≥ 10 on the COPD Assessment Test (CAT) or of ≥ 2 of the Medical Research Council (mMRC).
R. Pisi, M. Aiello, L. Calzetta, A. Frizzelli, P. Tzani, G. Bertorelli, A. Chetta   +6 more
doaj   +1 more source

Early respiratory diagnosis: benefits of enhanced lung function assessment

BMJ Open Respiratory Research, 2021
Introduction The National Health Service for England Long Term Plan identifies respiratory disease as one of its priority workstreams. To assist with earlier and more accurate diagnosis of lung disease they recommend improvement in delivery of quality ...
Ravi Mahadeva, Karl P Sylvester, Luke Youngs, M A Rutter, Ross Beech   +4 more
doaj   +1 more source

The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review

Biomedicines, 2021
Airway hyperresponsiveness (AHR) represents a central pathophysiological hallmark of asthma, with airway smooth muscle (ASM) being the effector tissue implicated in the onset of AHR.
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Giuseppina Bertorelli, Beatrice Ludovica Ritondo, Paola Rogliani, Alfredo Chetta   +6 more
doaj   +1 more source

Machine learning for prediction of asthma exacerbations among asthmatic patients: a systematic review and meta-analysis

BMC Pulmonary Medicine, 2023
Background Asthma exacerbations reduce the patient’s quality of life and are also responsible for significant disease burdens and economic costs.
Shiqiu Xiong, Wei Chen, Xinyu Jia, Yang Jia, Chuanhe Liu   +4 more
doaj   +1 more source

Accuracy of positive airway pressure titration through telemonitoring of auto‐adjusting positive airway pressure device connected to a pulse oximetry in patients with obstructive sleep apnea

The Clinical Respiratory Journal, 2023
Purpose In COVID‐19 era, all forms of access of patients to the sleep units should be reduced as much as possible when implementing telemedicine.
Antonio Foresi, Tommaso Vitale, Rosaria Prestigiacomo, Piera Ranieri, Marcello Bosi   +4 more
doaj   +1 more source

Clinical manifestations in patients with PI*MMMalton genotypes. A matter still unsolved in alpha‐1 antitrypsin deficiency

Respirology Case Reports, 2020
We report the genetic variants associated with alpha‐1 antitrypsin deficiency (AATD) in 117 patients admitted to our outpatient clinic and characterized by a serum concentration of AAT lower than 113 mg/dL.
Marina Aiello, Alberto Fantin, Chiara Longo, Ilaria Ferrarotti, Giuseppina Bertorelli, Alfredo Chetta   +5 more
doaj   +1 more source

Muscles and lungs: fatal attraction, but time for intervention

Monaldi Archives for Chest Disease, 2005
-
J.C. Winck, M. Gonçalves
doaj   +1 more source

Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma

Biomedicines, 2022
Inhaled corticosteroids (ICS) remain the mainstay of asthma treatment, along with bronchodilators serving as control agents in combination with ICS or reliever therapy.
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Elena Pistocchini, Beatrice Ludovica Ritondo, Paola Rogliani, Alfredo Chetta   +6 more
doaj   +1 more source

Clinical manifestations of a new alpha‐1 antitrypsin genetic variant: Q0parma

Respirology Case Reports, 2022
Alpha‐1 antitrypsin deficiency is an autosomal, codominant disorder caused by mutations of the SERPINA1 gene. Several mutations of SERPINA1 have been described associated with the development of pulmonary emphysema and/or chronic liver disease and ...
Marina Aiello, Annalisa Frizzelli, Laura Marchi, Ilaria Ferrarotti, Davide Piloni, Giovanna Pelà, Alessandro De Simoni, Lorenzo D'Aloisio, Luigino Calzetta, Alfredo Chetta   +9 more
doaj   +1 more source